Clinical Trials Sponsored by Theravance Biopharma

Total 1392 results

Theravance Biopharma
GlaxoSmithKline

Completed

Succinate Salt Version of GSK961081 for Healthy Volunteers

Pulmonary Disease, Chronic Obstructive

United Kingdom
Theravance Biopharma
GlaxoSmithKline

Completed

Study of GSK961081 in Healthy Volunteer Subjects

Pulmonary Disease, Chronic Obstructive

United Kingdom
Takeda
Theravance Biopharma

Completed

A Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of a Single Dose of Intravenous TD-8954 Compared With Metoclopramide in Critically Ill Patients With Enteral Feeding Intolerance

Enteral Feeding Intolerance

Australia
Theravance Biopharma
Viatris Inc.

Completed

Phase 4 COPD and Suboptimal Inspiratory Flow Rate (PIFR-2)

Chronic Obstructive Pulmonary Disease

United States
Theravance Biopharma
Alfasigma S.p.A.

Completed

The Diabetic and Idiopathic Gastroparesis Efficacy, Safety, and Tolerability (DIGEST) Study (DIGEST)

Gastroparesis
Theravance Biopharma
Alfasigma S.p.A.

Completed

Phase 2 Study of Velusetrag in Diabetic or Idiopathic Gastroparesis

Gastroparesis

United States
University of Michigan
Theravance Biopharma

Completed

Effect of Dialysis on the Pharmacokinetics of Telavancin in Patients With Chronic Kidney Disease Stage 5

End-Stage Renal Disease | Stage 5 Chronic Kidney Disease

United States
Mylan Inc.
Theravance Biopharma

Completed

Effects of TD-4208 on FEV1 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease, COPD

New Zealand
Mylan Inc.
Theravance Biopharma

Completed

A 7-Day Cross-over Study of QD (Once Daily) and BID (Twice Daily) TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease | COPD

United States
Mylan Inc.
Theravance Biopharma

Completed

A 28-Day Parallel Group Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)

COPD

United States
Mylan Inc.
Theravance Biopharma

Completed

Pharmacokinetics of TD-4208 in Patients With Severe Renal Impairment

Renal Impairment

United States
M.D. Anderson Cancer Center
Theravance Biopharma

Completed

Study to Evaluate the Safety and Efficacy of Telavancin in the Treatment of Gram Positive Bloodstream Infections in Cancer Patients

Bacteremia | Infection

United States
Mylan Inc.
Theravance Biopharma

Completed

A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPD

Chronic Obstructive Pulmonary Disease (COPD)

United States
Mylan Inc.
Theravance Biopharma

Completed

Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD

Chronic Obstructive Pulmonary Disease, COPD | Low Peak Inspiratory Flow Rate (PIFR)

United States
Mylan Inc.
Theravance Biopharma

Completed

Pharmacokinetics of TD-4208 in Patients With Moderate Hepatic Impairment

Hepatic Impairment

United States
Mylan Inc.
Theravance Biopharma

Completed

Thorough QT (TQT) Study of TD-4208 in Healthy Subjects

Cardiac Repolarization in Healthy Subjects

United States
Mylan Inc.
Theravance Biopharma

Completed

TD-4208 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male Subjects

Chronic Obstructive Pulmonary Disease (COPD)

United States
Mylan Inc.
Theravance Biopharma

Completed

A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

United States
Mylan Inc.
Theravance Biopharma

Completed

7 Days of TD-4208 in Subjects With Chronic Obstructive Pulmonary Disease

COPD

New Zealand
Mylan Inc.
Theravance Biopharma

Completed

Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD) (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

United States
Mylan Inc.
Theravance Biopharma

Completed

Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD) (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

United States
Theravance Biopharma
GlaxoSmithKline; Hammersmith Medicines Research

Completed

A Phase 1 (Ph1), Single Dose (SD), GSK961081 Absorption, Distribution, Metabolism, and Excretion (ADME) Study in Healthy Subjects

Pulmonary Disease, Chronic Obstructive

United Kingdom
University of Illinois at Chicago
Theravance Biopharma

Completed

Pharmacokinetics of Telavancin in Normal and Obese Subjects

Healthy

United States
University of California, Los Angeles
Mylan Pharmaceuticals Inc; Theravance Biopharma

Recruiting

Revefenacin in Acute Respiratory Insufficiency in COPD (RARICO)

COPD | Acute Respiratory Failure

United States
TheraVasc Inc.

Completed

Phase IIa: Safety, PK, & Tolerability of Sodium Nitrite in Patients With Peripheral Arterial Disease-SONIC

Peripheral Arterial Disease

United States
Theravant Corporation

Completed

Effects of Acleara Needle Insert on Acne

Acne Vulgaris

United States
Lantu Biopharma

Not yet recruiting

An Open-label Study of a Gene Therapy Product in Beta-Thalassemia

Beta-Thalassemia
Huons Biopharma

Not yet recruiting

To Evaluate HU-045 in the Treatment of Glabellar Lines(Phase III)

Glabellar Lines
Vor Biopharma

Recruiting

Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant

Leukemia, Myeloid, Acute

United States
United BioPharma

Not yet recruiting

Evaluating the Safety and Tolerability and Determining the PK and PD of Single Dose UB-221 in Chronic Spontaneous Urticaria

Chronic Idiopathic Urticaria
Kinnate Biopharma

Active, not recruiting

A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations

Intrahepatic Cholangiocarcinoma | Urothelial Carcinoma | Solid Tumor, Adult

United States, Korea, Republic of, Taiwan, China, Denmark, Spain
NImmune Biopharma

Terminated

Efficacy and Safety of Oral BT-11 in Moderate to Severe Crohn's Disease

Crohn's Disease

United States
CTI BioPharma

Completed

Pixantrone (BBR 2778) in Patients With Refractory Acute Myelogenous Leukemia (AML)

Acute Myelogenous Leukemia

United States
NImmune Biopharma

Completed

Safety Tolerability and Pharmacokinetics of Oral NIM-1324 in Healthy Adult Male and Female Volunteers

Normal Healthy Volunteers

Australia
NImmune Biopharma

Withdrawn

Safety and Efficacy of Oral BT-11 in Crohn's Disease Patients With Moderate to Severe Disease

Crohn's Disease
DS Biopharma

Completed

Efficacy and Safety Study of Orally Administered DS107 in Moderate to Severe Atopic Dermatitis Patients

Atopic Dermatitis

United States, South Africa
United BioPharma

Completed

Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UB-221 as an Add-on Therapy in CSU Patients

Urticaria Chronic

Taiwan
CTI BioPharma

Completed

Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant (PIX-R)

Diffuse Large B-cell Lymphoma | de Novo DLBCL | DLBCL Transformed From Indolent Lymphoma | Follicular Grade 3 Lymphoma

United States, Germany, Italy, United Kingdom, Hungary, France, Spain, Ukraine, Czechia, Austria, Belgium, Bulgaria, Denmark, Poland, Romania, Russian Federation, Slovakia
CTI BioPharma

Terminated

A Survival Study for Women With Advanced Lung Cancer Who Have Not Previously Received Chemotherapy. (PIONEER)

NSCLC

United States, Canada, Bulgaria, Romania, Russian Federation, Ukraine, Mexico, Argentina, Hungary, Poland, United Kingdom
CTI BioPharma

Terminated

Arsenic Trioxide in Treating Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
CTI BioPharma

Terminated

Polyglutamate Paclitaxel Plus Carboplatin Compared With Paclitaxel Plus Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer

Lung Cancer

Canada, United States
CTI BioPharma

Terminated

Pacritinib Versus Best Available Therapy to Treat Myelofibrosis

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

United States, Australia, Belgium, Czechia, France, Germany, Hungary, Italy, Netherlands, New Zealand, Russian Federation, United Kingdom
NuSirt Biopharma

Completed

The Effect Of NS-0200 and NS-0300 Versus Placebo on Weight In Obesity

Obesity

United States
DS Biopharma

Completed

Efficacy and Steroid Sparing Potential Study of DGLA Cream in Early Childhood Patients With Moderate to Severe Atopic Dermatitis

Atopic Dermatitis

Ireland
Array BioPharma

Completed

Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations

Metastatic Colorectal Cancer

United States, Australia, Belgium, Canada, France, Israel, Italy, Netherlands, Singapore, Spain
DS Biopharma

Completed

Safety and Efficacy Study of Orally Administered DS102 in Healthy Subjects

Healthy

Ireland
Pronova BioPharma

Completed

Icosabutate - A Phase I, Single Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Subjects

Healthy

United Kingdom
Pronova BioPharma

Completed

Bioavailability of Omega-3 Food Supplements in Healthy Subjects

Healthy

United Kingdom
Pronova BioPharma

Completed

[14C] Icosabutate -A Phase I Absorption, Metabolism and Excretion Study

Healthy

United Kingdom
CTI BioPharma

Completed

A Trial in Patients With Diffuse Large-B-cell Lymphoma Comparing Pixantrone Against Doxorubicin (RAPID)

Diffuse Large-Cell Lymphoma

United States, Germany, Canada, Italy, France

Clinical Trials Sponsored by Theravance Biopharma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ecuador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations